General Updates

Date: October 01, 2026 National Stock Exchange of India Limited BSE Limited Symbol: NSE: GRANULES: BSE: 532482 Dear Sir, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of Wholly Owned Foreign Subsidiary Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable SEBI Circular, we wish to inform you that the Company has incorporated a wholly owned foreign subsidiary in the name of “TRITON FARMACEUTICA DO BRASIL LTDA in Brazil. In terms of the Listing Regulations read with the SEBI Circular No SEBI/HO/CFD/CFD- PoD1/P/CIR/2023/123 dated July 13, 2023 on Disclosure of material events/information, we are furnishing herewith the details in the enclosed Annexures respectively. Kindly take the above information on record. For GRANULES INDIA LIMITED CHAITANYA TUMMALA (COMPANY SECRETARY & COMPLIANCE OFFICER) Encl: Annexure REGISTERED OFFICE Granules India Limited CIN: L24110TG1991PLC012471 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India Contact Us: Tel: +91-40-69043500 |Fax: +91-40-23115145| mail@granulesindia.com www.granulesindia.com Annexure I Disclosure under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 S. No. Particulars Description 1. Name of the target entity, details in brief such as size, TRITON FARMACEUTICA DO turnover etc. BRASIL LTDA It is a newly incorporated Company in country of Brazil and has not started its business. 2. Whether the acquisition would fall within related party Upon incorporation of TRITON transaction(s) and whether the promoter/ promoter group/ FARMACEUTICA DO BRASIL group companies have any interest in the entity being LTDA, it became a related party acquired. If yes, the nature of interest and details thereof and to the Company. whether the same is done at “arms-length” The Promoter & Promoter Group of the Company do not have any interest in the entity incorporated. 3. The industry to which the entity being acquired Pharmaceuticals 4. Objects and impacts of acquisition (including but not limited WoS is being incorporated to to, disclosure of reasons for acquisition of target entity, if its manufacture, promote, sale and business is outside the main line of business of the listed distribute pharmaceuticals and entity) other related product(s) in Country of Brazil 5. Brief details of any governmental or regulatory approvals Prior approval of the Reserve required for the acquisition Bank of India (RBI) under the automatic route. 6. Indicative time period for completion of the acquisition Not Applicable 7. Nature of consideration - whether cash consideration or Not Applicable share swap and details of the same 8. Cost of acquisition or the price at which the shares are Not Applicable acquired REGISTERED OFFICE Granules India Limited CIN: L24110TG1991PLC012471 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India Contact Us: Tel: +91-40-69043500 |Fax: +91-40-23115145| mail@granulesindia.com www.granulesindia.com